CEP135 and glioma: Specifically, CEP135 was able to stratify patients with urothelial bladder carcinoma (BLCA), low-grade glioma (LGG), and sarcoma (SARC) cancers (Fig. 3A, B), with the most significant effect obtained in patients with LGG malignancies.